Kappa-opioid receptor agonists differentially affect the release of neurohypophysial hormones.
The influence of kappa-opioid receptor agonists and antagonists on release of oxytocin and vasopressin was examined in isolated rat neurointermediate lobes. Electrically evoked release of oxytocin and vasopressin was concentration-dependently inhibited by the specific kappa-receptor agonist U69593, whereas bremazocine only inhibited the secretion of oxytocin markedly. Treatment with naloxone enhanced the evoked release of oxytocin significantly without effect on vasopressin secretion. The U69593-mediated inhibition of oxytocin release was abolished by naloxone, whereas that of vasopression was unaffected. Naloxone did not reverse the bremazocine-induced inhibition of hormone release. The data support the theory of an inhibiting endogenous control over oxytocin secretion and show that the release of oxytocin and vasopresin is differentially affected by the two K-receptor agonists.
Fjalland
B
B
Department of Biology, Royal Danish School of Pharmacy, Universitetsparken 2, Copenhangen.
Christensen
J D
JD
D000818:Animals; D044482:Benzeneacetamides; D001575:Benzomorphans / Q000494:pharmacology; D004558:Electric Stimulation; D005260:Female; D066298:In Vitro Techniques; D009270:Naloxone / Q000494:pharmacology; D009411:Nerve Endings / Q000187:drug effects / Q000378:metabolism; D010121:Oxytocin / Q000378:metabolism; D010909:Pituitary Hormones, Posterior / Q000378:metabolism*; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000378:metabolism*; D017473:Receptors, Opioid, kappa; D014667:Vasopressins / Q000378:metabolism
D044482:Benzeneacetamides; D001575:Benzomorphans; D010909:Pituitary Hormones, Posterior; D011759:Pyrrolidines; D011957:Receptors, Opioid; D017473:Receptors, Opioid, kappa; D014667:Vasopressins; D009270:Naloxone; D010121:Oxytocin; C027248:bremazocine; C045444:U 69593